Ulrich Keilholz

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Alexander M.M. Eggermont, Stefan Suciu, Mario Santinami et al. · The Lancet · 2008 · 642 citations

Medicine, Oncology, Pharmacotherapy +14

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Olivier Michielin, Alexander C. J. van Akkooi, Paolo A. Ascierto et al. · Annals of Oncology · 2019 · 621 citations · Full text

Medicine, Dermatology, Oncology +14

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

Axel Hauschild, Sanjiv S. Agarwala, Uwe Trefzer et al. · Journal of Clinical Oncology · 2009 · 545 citations · Full text

Medicine, Oncology, Pharmacology +15

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Reinhard Dummer, Axel Hauschild, Nicole Lindenblatt et al. · Annals of Oncology · 2015 · 393 citations · Full text

Medicine, Dermatology, Oncology +14